Catherine Diefenbach
DLBCL immunology
Catherine Diefenbach, MD
New York, NY
United States
NYU Grossman School of Medicine
I am a translational lymphoma researcher and associate professor at the NYU Perlmutter Cancer Center (PCC). My research focuses on the relationship between lymphoma, microenvironment, and systemic immunity. I lead an R01 funded study of the microbiome in DLBCL, and and serve as PI on a multi-investigator R01 investigating new immune strategies for CAR T cells. I have presented data on immune profiling in Hodgkin lymphoma (HL) at national and international meetings. Clinically, I have led the effort to integrate immune based approaches into lymphoma therapy, through development of the intergroup Phase 2 protocol E4412 combining brentuximab, nivolumab, and ipilimumab in relapsed HL. I have obtained funding for my research from: the NCI, the ACS, the Lymphoma Research Foundation, Doris Duke (internally awarded), and the NCI Clinical Investigator Team Leader Award for my work with ECOG-ACRIN. My expertise in lymphoma immunology makes me well qualified to lead this current project.
Program Name(s)
Translational Research Program
Project Title
T cell Memory in Cure of Diffuse Large B Cell Lymphoma: An Investigation of the Immune Interactome
Abhilash Barpanda, PhD
San Francisco, CA
United States
University of California, San Francisco
I am a postdoctoral researcher at UCSF, aiming to advance proteomic technologies for target discovery and redefine immunotherapy in blood cancers. In Dr. Arun Wiita's lab, I focus on identifying novel surface antigens in hematological malignancies like AML and multiple myeloma. By combining proteomics with immunotherapy strategies, I aim to bridge scientific discovery and clinical applications, improving outcomes for patients. My PhD in clinical proteomics from IIT-Bombay provided a foundation in biomarker discovery and translational research. I specialize in mass spectrometry-based proteomics, applying quantitative and targeted approaches to explore cancer proteomes and identify "proteoforms" as therapeutic targets. Building on promising data, my research explores surface protein post-translational modifications as a new class of immunotherapy targets, positioning me to become an independent investigator developing breakthrough therapies for blood cancers.
Program Name(s)
Career Development Program
Project Title
“Open-Surfaceomics” for Identifying Novel Surface PTMs as Immunotherapy Targets in AML
Jalpa Doshi
Equity in Access
Jalpa Doshi, PhD
Philadelphia, PA
United States
Perelman School of Medicine at the University of Pennsylvania
Jalpa Doshi, PhD, is a Professor at the University of Pennsylvania and Director of Value Based Insurance Design Initiatives at the Center for Health Incentives and Behavioral Economics. Her research program aims to advance our understanding of how pharmaceuticals can be better accessed and utilized in the health care system to improve health outcomes while balancing costs. She has been a national leader in applying powerful health economics, outcomes research, and policy methods to address issues related to pharmaceutical access, costs, outcomes, and value. Her research has received widespread attention from the media including the New York Times and the Wall Street Journal and has directly influenced policies of public and private insurers. For example, she was the first to produce rigorous empirical research advocating for the closure of the “donut hole” (executed under the Affordable Care Act) and institution of an annual out-of-pocket maximum with “smoothing” (executed under the Inflation Reduction Act) under Medicare Part D. Her work documenting negative consequences of cost sharing among veterans was cited in arguments that kept the VA from increasing drug copayments. Her research on the burden of prior authorization policies for novel cholesterol-lowering agents was used to work with national insurers to appropriately reduce their policy restrictions. In recognition of her work, she has received numerous awards and honors from national and international organizations.
Program Name(s)
Equity in Access
Project Title
Ivan Odak
Non-Hodgkin's Lymphoma immunotherapy
Ivan Odak, PhD
New York, NY
United States
Icahn School of Medicine at Mount Sinai
My name is Ivan Odak and I am a postdoctoral researcher in the Brody lab. I am an accomplished researcher with 20 authored papers, 9 of which as first or last author. I obtained my PhD summa cum laude from Hannover Biomedical Research School in Germany, where I also worked as a postdoc in the lab of Reinhold Förster. Though challenging, I find science primarily enjoyable, and I like using my skills to tackle important questions in the field of immuno-therapy. The colleagues see me as tireless force in the workplace and I often use my positive attitude and energy to motivate others. My ultimate goal is to establish my own lab dedicated to research and discovery of cancer immunotherapies.
Program Name(s)
Career Development Program
Project Title
Prevention of antigen escape by modulation of off-target tumor killing in T cells
Mala Shanmugam
myeloma
Mala Shanmugam, PhD
Atlanta, GA
United States
Emory University
I am a cancer biologist and Associate Professor in the Department of Hematology and Medical Oncology at the Winship Cancer Institute, Emory University School of Medicine. I am a recipient of the Lexie Clayton Impact Award from The Leukemia & Lymphoma Society. My research focus includes understanding how metabolic states regulate specific cancer hallmarks such as the evasion of cell death; proliferation and growth; and invasion and metastasis to identify targetable metabolic vulnerabilities. We have an interest in investigating how mitochondrial metabolism impacts multiple myeloma therapy efficacy and more recently are examining how the bone marrow niche is regulated by neural signaling. My research lab comprised of talented scientist trainees, who in collaboration with the Winship team of multiple myeloma physicians and scientists are endeavoring to ask provocative and innovative questions for curing multiple myeloma.
Program Name(s)
Translational Research Program
Project Title
Deciphering the metabolic basis for t(11;14) multiple myeloma venetoclax sensitivity
Investigating anti-neoplastic effects of beta blockers in multiple myeloma
Jonathan Licht
DNA biology, myeloma
Jonathan Licht, MD
Gainesville, FL
United States
University of Florida
Jonathan D. Licht, MD, is the Director of the University of Florida Health Cancer Institute, leading it to become the 72nd NCI-designated center in the country. Dr. Licht’s laboratory studies the role of abnormal function of histone methyltransferases and demethylases in malignancies such as multiple myeloma and acute lymphoblastic leukemia and recently described a new class of mutations in histones in cancer. NCI funded for nearly 35 years, Dr. Licht is also Principal Investigator of a Leukemia and Lymphoma Society (LLS) Specialized Center of Research, now in its 17th year of funding. He is the founding Editor- in-Chief of Blood Neoplasia, a new journal of the American Society of Hematology, and serves on the editorial boards of Cancer Research, Oncogene and Clinical Cancer Research. Dr. Licht was the first chair of the AACR Taskforce on Hematological Malignancies of and currently is Chair of the Medical/Scientific Board of the LLS. Dr. Licht has published more than 230 articles, reviews and book chapters and has mentored over 40 graduate students and postdoctoral fellows and 20 faculty members.
Program Name(s)
Specialized Center of Research Program
Project Title
Epigenetic Mechanisms and Targeting in Hematological Malignancy
Armin Rashidi
gut bacteria and transplant success
Armin Rashidi, MD, PhD
Seattle, WA
United States
Fred Hutchinson Cancer Center
I am an Associate Professor of Medicine (Hematology, Oncology, and Transplantation) at Fred Hutch with clinical trial and computational expertise. I have a broad background with a Master of Science in Clinical Investigation combined with computational sciences training, including a PhD in evolutionary models of aging and a KL2 career development award focused on microbiome bioinformatics. I leverage my clinical and computational expertise to make cancer treatment safer by improving supportive care. I characterize microbiota disruptions in patients with cancer, investigate their clinical significance, and test microbiota restorative therapeutics to improve clinical outcomes. Recently, I led the largest clinical trial of FMT in allogeneic stem cell transplant recipients to date. We used findings from this trial to design the proposed randomized placebo-controlled phase 2 trial of third-party FMT to prevent aGVHD after transplantation.
Program Name(s)
Academic Clinical Trials Program (ACT)
Project Title
Fecal microbiota transplantation to prevent acute GVHD after allogeneic stem cell transplantation
Elliot Stieglitz
CMML
Elliot Stieglitz, MD
San Francisco, CA
United States
University of California, San Francisco
Dr. Elliot Stieglitz is a physician-scientist at the University of California, San Francisco whose research focuses on children diagnosed with juvenile myelomonocytic leukemia (JMML). He recently chaired a study, ADVL1512, a phase II clinical trial that tested the safety of trametinib in children with relapsed JMML. This trial met its primary objective and closed to accrual at the end of 2022. Dr. Stieglitz’s main laboratory focus is on developing novel therapies for JMML including CAR-T cells. He has generated patient-derived xenograft (PDX) models of JMML that will serve as the pre-clinical model in which to test CAR-T cells on this grant. These PDXs were generated in collaboration with Dr. Eric Padron, a key opinion leader in CMML and a collaborator on this grant. Dr. Stieglitz has also collaborated extensively with Dr. Tasian, an international leader in CAR-T therapy who is a Co-PI on this grant. This multi-disciplinary team will work together to advance CLL-1 CAR-T cells and trametinib into the clinic for CMML and JMML patients.
Program Name(s)
CMML Initiative
Project Title
CLL-1 CAR-T cells and trametinib for the treatment of Ras-mutated CMML and JMML
Martin Dreyling
Mantle Cell Lymphoma
Martin Dreyling, MD
Ludwig Maximilian University of Munich
Martin Dreyling is Professor of Medicine and head of the lymphoma programme at the Department of Medicine III, LMU Hospital Munich. He studied at the Universities of Düsseldorf, Giessen, Tübingen and Würzburg, and completed his clinical training at the Universities of Bonn, Münster, Göttingen and Munich. In addition, he was visiting scientist at the University of Chicago.
His scientific focus is on the molecular basis of malignant transformation, cell cycle dysregulation and secondary genetic alterations as well as biological prognostic factors in malignant lymphoma. He is also interested in innovative therapeutic approaches, including molecular targeted approaches like inhibitors of the B-cell receptor pathway and immunological approaches.
Prof. Dreyling is coordinator of the European MCL Network and president of the German Lymphoma Alliance as well as EHA executive board member. He has co-authored numerous scientific papers and abstracts in international peer-reviewed journals.
Program Name(s)
Mantle Cell Lymphoma Research Initiative
Project Title
MULTIlayer Predictive models for relapsed MCL after ibrutinib as first line therapY (MULTIPLY)
Auron Therapeutics
degrader, AML, MDS
Auron Therapeutics
Newtown, MA
United States
TAP Partner
Auron is a platform-powered company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease. Auron uses AI and machine learning to compare cell states and identify novel drug targets, optimal development models, and biomarkers to facilitate proper patient selection, ultimately accelerating the development of effective and durable therapies.
Program Name(s)
Therapy Acceleration Program
Project Title
A phase 1 study of AUTX-703, a KAT2A/B degrader, in patients with AML or MDS
BioInvent
immunotherapy, indolent NHL, CTCL
BioInvent
Lund,
Sweden
TAP Partner
BioInvent International AB is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.
Program Name(s)
Therapy Acceleration Program
Project Title
Marco Ruella
Immunotherapy for T-cell lymphoma
Marco Ruella, MD
Philadelphia, PA
United States
Perelman School of Medicine at the University of Pennsylvania
Dr. Marco Ruella is a physician-scientist and assistant professor at the University of Pennsylvania. He treats patients with blood cancers and focuses on using immunotherapy, where the body’s own immune system is harnessed to fight cancer. His research looks at why some cancers return after CAR T-cell therapy and aims to design new treatments to prevent this. Dr. Ruella earned his medical degree in Italy and completed advanced training in the U.S. He has received many awards for his work, including from the American Society for Clinical Investigation and the Leukemia & Lymphoma Society. Dr. Ruella has published widely, holds multiple patents, and advises companies in cancer immunotherapy. He also founded viTToria Biotherapeutics to help bring new treatments to patients.
Program Name(s)
Career Development Program
Translational Research Program
Project Title
β-Hydroxybutyrate To Enhance CAR T Cell Immunotherapy Against Hematological Cancers